Compare NUKK & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUKK | ACRV |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.0M | 82.7M |
| IPO Year | N/A | 2022 |
| Metric | NUKK | ACRV |
|---|---|---|
| Price | $5.12 | $2.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | ★ 1.6M | 531.8K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.34 | $1.05 |
| 52 Week High | $78.32 | $8.00 |
| Indicator | NUKK | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 59.35 |
| Support Level | $5.89 | $2.44 |
| Resistance Level | $7.44 | $2.73 |
| Average True Range (ATR) | 0.87 | 0.18 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 14.10 | 65.79 |
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.